RxDoctor Payments Data

Laura Taylor, PA

Physician Assistant · Rolla, MONPI 1114284759

Payments from drug & device makers

$5,817in general payments, 2019–2025

Across 367 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$730
  • Sun Pharmaceutical Industries Inc.$576
  • Regeneron Healthcare Solutions, Inc.$476
  • Sanofi$418
  • Pfizer$414
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,58196%
  • Education$2364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,817 in reported general payments places this provider in the 90th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$27,872
Medicare patients
87
Services billed
769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$221,214
OtezlaApremilast19$90,849
Cosentyx Sensoready (2 Pens)Secukinumab12$86,317
Dupixent PenDupilumab13$48,546
Halobetasol Propionate30$1,653
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip45$1,400
Clobetasol Propionate35$1,049
Clindamycin Phosphate23$796
Imiquimod42$531
Doxycycline Hyclate25$397
Ketoconazole31$307
Triamcinolone Acetonide44$291
Fluconazole11$270
Hydroxyzine Hcl26$259
Nystatin11$237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$288$90,84919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Rolla

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →